Dietary gamma-linolenic acid suppresses aortic smooth muscle cell proliferation and modifies atherosclerotic lesions in apolipoprotein E knockout mice.
The present study was conducted to evaluate the antiatherogenic effects of dietary gamma-linolenic acid (GLA) (primrose oil) in apolipoprotein E (apoE) genetic knockout mice. Five-wk-old male mice were fed cholesterol-free diets containing 10 g/100 g lipid as corn oil (CO) [control diet, 0 mol/100 mol GLA and (n-3) polyunsaturated fatty acids (PUFA)], primrose oil (PO, 10 mol/100 mol GLA), fish oil-CO mix [FC; 9:1 wt/wt, 0 mol/100 mol GLA and 17 mol/100 mol (n-3) PUFA] or fish oil-PO mix [FP, 1:3 wt/wt, 8 mol/100 mol GLA and 5 mol/100 mol (n-3) PUFA] for 15 wk. Subsequently, diets were supplemented with cholesterol (1.25 g/100 g) and sodium cholate (0.5 g/100 g) and fed for an additional 10 and 16 wk. Plasma cholesterol and triglyceride levels generally did not differ among groups at 20, 30 and 36 wk of age. Mice fed GLA-containing diets (PO and FP) had significantly (P < 0.05) higher liver phospholipid levels of dihomo-gamma-linolenic acid, the elongated product of GLA, relative to CO and FC groups. Consumption of GLA (PO and FP diets) significantly reduced (P < 0.05) aortic vessel wall medial layer thickness at 20 and 30 wk. A parallel GLA-dependent suppression in the number of proliferating (proliferating cell nuclear antigen positive) aortic smooth muscle cells was also observed. Diets containing either GLA or (n-3) PUFA reduced (P < 0.05) atherosclerotic lesion size in 30-wk-old mice. These results indicate that dietary GLA can suppress smooth muscle cell proliferation in vivo and retard the development of diet-induced atherosclerosis in apoE knockout mice.
Fan
Y Y
YY
Molecular and Cell Biology Section, Faculty of Nutrition, Texas A&M University, College Station, Texas 77840, USA.
Ramos
K S
KS
Chapkin
R S
RS
D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects; D001057:Apolipoproteins E / Q000172:deficiency*; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002784:Cholesterol / Q000097:blood; D004042:Dietary Fats, Unsaturated / Q000494:pharmacology* / Q000627:therapeutic use; D005227:Fatty Acids / Q000032:analysis; D005228:Fatty Acids, Essential / Q000494:pharmacology; D008041:Linoleic Acids; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D031665:Oenothera biennis; D010743:Phospholipids / Q000378:metabolism; D010938:Plant Oils; D014280:Triglycerides / Q000097:blood; D017965:gamma-Linolenic Acid / Q000494:pharmacology* / Q000627:therapeutic use
D001057:Apolipoproteins E; D004042:Dietary Fats, Unsaturated; D005227:Fatty Acids; D005228:Fatty Acids, Essential; D008041:Linoleic Acids; D010743:Phospholipids; D010938:Plant Oils; D014280:Triglycerides; C028498:evening primrose oil; D017965:gamma-Linolenic Acid; D002784:Cholesterol